All In Biotech

Drug Trial Radar · NCT03624543

CFI-400945 in Patients With Advanced/Metastatic Breast Cancer

A Phase II Study of CFI-400945 in Patients With Advanced/Metastatic Breast Cancer

Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

51

Actual

Start

Feb 14, 2019

Primary completion

Nov 30, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Canadian Cancer Trials GroupResearch network
Sponsor type
Research network
Collaborators
Stand Up To Cancer Canada-Canadian Cancer Society Breast Cancer Dream Team
First posted
Aug 10, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The standard or usual treatment for this disease is to undergo chemotherapy to slow the spread of the disease and relieve some symptoms of cancer. Patients will have already had at least one chemotherapy treatment for their disease at this stage.

Conditions

  • Breast Cancer

Interventions

  • CFI-400945Drug

    32mg; 28 day cycles; Cycle 1: Days 1-7 then 15-21 Cycle 2 onward: Daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response defined by RECIST 1.1Time frame: 2 years

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Juravinski Cancer Centre at Hamilton Health Sciences

    Hamilton, Ontario, Canada

  • London Regional Cancer Program

    London, Ontario, Canada

  • Ottawa Hospital Research Institute

    Ottawa, Ontario, Canada

  • Odette Cancer Centre

    Toronto, Ontario, Canada

  • University Health Network

    Toronto, Ontario, Canada

  • Allan Blair Cancer Centre

    Regina, Saskatchewan, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.